Advertisement

Topics

BRIEF-Novo Nordisk says Xultophy demonstrates similar glucose control to insulin glargine

22:25 EST 1 Dec 2016 | Reuters

* Says Xultophy (IDegLira) demonstrates similar glucose control with reduced risk of hypoglycaemia and a superior weight profile compared to basal-bolus therapy

Original Article: BRIEF-Novo Nordisk says Xultophy demonstrates similar glucose control to insulin glargine

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Novo Nordisk says Xultophy demonstrates similar glucose control to insulin glargine"

Quick Search
Advertisement